Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera PTG-300 treatment demonstrates robust clinical response and provides clinically meaningful dose related control of hematocrit values on individual patient basis Results to be presented today by Ronald Hoffman, M.D., Director of the Myeloproliferative Diseases Program at The Icahn […]
Protagonist Therapeutics early Phase 2 results for Polycythemia Vera Treatment Encouraging
5:01 pm By
Phyllis George dies from Polycythemia Vera complications
1:58 pm By
The MPN Community needs a Celebrity Spokesperson to bring awareness of our “Rare Blood Disease” by David Wallace I’m saddened to hear that former Kentucky first lady and Miss America, Phyllis George passed away from a “rare blood disease” at 70. She was a true pioneer in the TV broadcast industry, as the first woman […]
Coping with COVID-19
4:39 pm By
Easy Ways to Stay Calm by Lou Ann Donovan How Are You Coping with the Coronavirus Pandemic? The COVID-19 pandemic has brought many changes in how we live our lives now. It has brought uncertainty, changes to daily routines, financial concerns and social isolation. You may be worrying about getting sick or what the future […]
The New WHO classification for Essential Thrombocythemia calls for revision of available evidences
7:56 am By
Abstract In the 2016 revised classification of myeloproliferative neoplasms pre-fibrotic primary myelofibrosis (pre-PMF) was recognized as a separate entity, distinct from essential thrombocythemia (ET). Owing that the majority of cases falling in the pre-PMF category were previously diagnosed as ET, one may question about the need to re-evaluate the results of epidemiologic, clinical, and molecular […]
NAC N-acetylcysteine Supplement may benefit MPN patients
7:04 pm By
by Deb Wesloh N-acetylcysteine (NAC) supplement has shown to have Antioxidant and Anti-inflammatory Properties Polycythemia vera, essential thrombocythemia and myelofibrosis make up a class of blood cancers called myeloproliferative neoplasms or MPNs. MPNs are characterized by the over-production of red or white blood cells or platelets in the bone marrow. MPNs increase the risk of […]
Ocular Manifestations in Patients with Philadelphia Negative Myeloproliferative Neoplasms
2:43 pm By
Abstract: The major complications of Philadelphia‐negative (Ph‐Negative) myeloproliferative neoplasms (MPNs) are thrombosis, haemorrhage and leukemic transformation. As systemic and haematological diseases, MPNs have the potential to affect many tissues and organs. Some complications lead to the diagnosis of MPNs, but other signs and symptoms are often misdiagnosed or neglected as a sign of MPN disease. […]
Suffering from Signs and Symptoms of Polycythemia Vera?
6:37 pm By
Thrilled for Polycythemia Vera (PV) Diagnosis! Publisher’s Note (David Wallace): It’s rare that I will accept an anonymous patient story, just one other in 7 years. Starting back in October 2019, a gentleman who found PV Reporter at the top of a google search, reached out offering to share a “summary” of his story. We […]
MPN Facebook Group Leader, Patient Advocate Spotlight
5:08 pm By
Tips on Living with MPN – Reflections on 2020 by Christine Kennedy As the New Year is under way, its a time of reflection. MPN are an evolving disease. The difference in the years of running MPN groups has shown in what were arguments into basic knowledge of diagnoses. The arguments of diagnoses have settled […]
The AACR-MPM Oncology Charitable Foundation Announces First Grants to Support Transformative Cancer Research
12:05 pm By
PHILADELPHIA, PA and CAMBRIDGE, MA – Two grants for research that could transform cancer therapies have been funded through an innovative partnership between the American Association for Cancer Research (AACR) and MPM Capital through its management of the UBS Oncology Impact Fund (OIF). This unique grant program allows investigators who can make a significant impact […]
Ropeginterferon Effective Treatment for Polycythemia Vera
5:41 pm By
Thrombotic Risk Reduction and High Rate of Complete Molecular Response with the Long Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study, ASH 2019 interview with Dr. Kiladjian by David Wallace Dr. Jean Jacques Kiladjian, Professor of Clinical Hematology, Hopital Saint-Louis, Paris, France interviews with David Wallace, PV Reporter at […]
